JP2005500981A - ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド - Google Patents

ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド Download PDF

Info

Publication number
JP2005500981A
JP2005500981A JP2002557409A JP2002557409A JP2005500981A JP 2005500981 A JP2005500981 A JP 2005500981A JP 2002557409 A JP2002557409 A JP 2002557409A JP 2002557409 A JP2002557409 A JP 2002557409A JP 2005500981 A JP2005500981 A JP 2005500981A
Authority
JP
Japan
Prior art keywords
polypeptide
pharmaceutically acceptable
hiv
day
ccr5 antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002557409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500981A5 (enExample
Inventor
バヒジェ エム． バロウディー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005500981A publication Critical patent/JP2005500981A/ja
Publication of JP2005500981A5 publication Critical patent/JP2005500981A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2002557409A 2000-12-19 2001-12-17 ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド Pending JP2005500981A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25665700P 2000-12-19 2000-12-19
PCT/US2001/048802 WO2002056902A2 (en) 2000-12-19 2001-12-17 Ccr5 antagonist and dp-178 polypeptide for treating viral infections

Publications (2)

Publication Number Publication Date
JP2005500981A true JP2005500981A (ja) 2005-01-13
JP2005500981A5 JP2005500981A5 (enExample) 2005-04-21

Family

ID=22973061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002557409A Pending JP2005500981A (ja) 2000-12-19 2001-12-17 ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド

Country Status (12)

Country Link
US (1) US20050065319A1 (enExample)
EP (1) EP1385534A2 (enExample)
JP (1) JP2005500981A (enExample)
CN (1) CN1481251A (enExample)
AR (1) AR031931A1 (enExample)
BR (1) BR0116253A (enExample)
CA (1) CA2431919A1 (enExample)
HU (1) HUP0302241A3 (enExample)
MX (1) MXPA03005526A (enExample)
NO (1) NO20032769L (enExample)
WO (1) WO2002056902A2 (enExample)
ZA (1) ZA200304560B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
BRPI0410360A (pt) * 2003-05-16 2006-08-01 Univ Maryland Biotech Inst composições para a sub-regulação da expressão de ccr5 e métodos para seu uso
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
JP2009517474A (ja) * 2005-11-30 2009-04-30 シェーリング コーポレイション Ｃｃｒ５拮抗剤およびｃｘｃｒ４拮抗剤の組み合わせを含む組成物
EP1976497A2 (en) * 2005-12-01 2008-10-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
WO2013127299A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CA2224008C (en) * 1995-06-07 2009-08-18 Trimeris, Inc. The treatment of hiv and other viral infections using combinatorial therapy
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
CA2365900A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PT1175402E (pt) * 1999-05-04 2005-11-30 Schering Corp Derivados da piperidina uteis como antagonistas ccr5
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists

Also Published As

Publication number Publication date
NO20032769L (no) 2003-08-18
HUP0302241A2 (hu) 2003-11-28
US20050065319A1 (en) 2005-03-24
WO2002056902A3 (en) 2002-12-05
WO2002056902A2 (en) 2002-07-25
CA2431919A1 (en) 2002-07-25
ZA200304560B (en) 2005-07-27
BR0116253A (pt) 2006-05-02
MXPA03005526A (es) 2003-10-06
EP1385534A2 (en) 2004-02-04
CN1481251A (zh) 2004-03-10
HUP0302241A3 (en) 2005-06-28
NO20032769D0 (no) 2003-06-18
AR031931A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
AU776541B2 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
JP4248251B2 (ja) Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト
JPH11507632A (ja) 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
US6635646B1 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
JP2005500981A (ja) ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド
US20020142940A1 (en) Method of inhibiting viral infection using HMG-COA reductase inhibitors and isoprenylation inhibitors
CA2338983A1 (en) Prevention and treatment of viral disease
US20070123538A1 (en) Compositions comprising a combination of CCR5 and CXCR4 antagonists
TW200427682A (en) Piperidine derivatives useful as ccr5 antagonists
AU2002245148A1 (en) CCR5 antagonist and DP-178 polypeptide for treating viral infections
KR20080098541A (ko) Ｈｉｖ 치료에 유용한 ｃｃｒ5 길항제
US20020182179A1 (en) HIV Therapy
MX2008007042A (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070314